Cited 10 times in
Effect of Interleukin-7 on Radiation-Induced Lymphopenia and Its Antitumor Effects in a Mouse Model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 변화경 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 한수철 | - |
dc.date.accessioned | 2021-04-29T17:23:57Z | - |
dc.date.available | 2021-04-29T17:23:57Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182323 | - |
dc.description.abstract | Purpose: Local ionizing radiation (IR) can lead to systemic lymphocyte depletion, which is associated with poor survival outcomes in patients with cancer. Interleukin-7 (IL-7) plays an important role in lymphocyte homeostasis; however, its role in alleviating radiation-induced lymphopenia remains unclear. Hence, we established a radiation-induced lymphopenia animal model and evaluated the effect of exogenous IL-7 administration. Methods: C3H/HeN mice underwent x-ray irradiation of 30 Gy in 10 fractions at the right hind limbs. Next, 10 mg/kg of IL-7 was injected subcutaneously, and the lymphocyte count in blood was measured. Murine hepatocellular carcinoma (HCa-1) cells were inoculated subcutaneously into the right thighs of tumor model mice, which underwent the same treatment. Results: In the naïve mouse model, the decreased CD45+ cell count after irradiation gradually recovered to the initial level over 3 weeks in the IR group, whereas it markedly increased to 373% of the initial level in 1 week in the IR+IL-7 group. Similar trends were observed for the CD3+, CD8+, CD4+, regulatory T cells, and CD19+ B cell counts. Similar findings were observed in the tumor mouse model. CD8+ and CD4+ T cell infiltration in tumor specimens was higher in the IL-7 and IR+IL-7 groups than in the nontreated and IR groups. Tumor growth was significantly more suppressed in the IR+IL-7 group than in the IR group. The median survival time was significantly longer in the IR+IL-7 group (not reached) than in the IR (56 days; P = .0382), IL-7 (36 days; P = .0004), or nontreated groups (36 days; P < .0001). Conclusions: Administration of exogenous IL-7 after IR not only restored lymphocyte counts but also enhanced the antitumor effect. Exogenous IL-7 can be beneficial in overcoming radiation-induced lymphopenia and in enhancing the treatment outcome in combination with radiation therapy, which needs validation through future clinical studies. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Science Inc. | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Effect of Interleukin-7 on Radiation-Induced Lymphopenia and Its Antitumor Effects in a Mouse Model | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Hwa Kyung Byun | - |
dc.contributor.googleauthor | Kyoung-Jin Kim | - |
dc.contributor.googleauthor | Su Chul Han | - |
dc.contributor.googleauthor | Jinsil Seong | - |
dc.identifier.doi | 10.1016/j.ijrobp.2020.12.004 | - |
dc.contributor.localId | A05136 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A05942 | - |
dc.relation.journalcode | J01157 | - |
dc.identifier.eissn | 1879-355X | - |
dc.identifier.pmid | 33321193 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0360301620346502 | - |
dc.contributor.alternativeName | Byun, Hwa Kyung | - |
dc.contributor.affiliatedAuthor | 변화경 | - |
dc.contributor.affiliatedAuthor | 성진실 | - |
dc.contributor.affiliatedAuthor | 한수철 | - |
dc.citation.volume | 109 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1559 | - |
dc.citation.endPage | 1569 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.109(5) : 1559-1569, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.